The Effects of SGLT2 Inhibitors on Lipid Profile and Kidney Function in Patients with Chronic Kidney Disease Regardless of Diabetes and Hypertension Status
This study showed that the use of SGLT2i reduced total Chol in all patients with CKD during the 24-month follow-up, regardless of diabetes mellitus (DM) status. No significant differences were observed for the Tg, LDLc, and HDLc values.
Authors
- Jelena Pavlović (ORCID: https://orcid.org/0009-0002-4249-9551)
- Stefan Janković (ORCID: https://orcid.org/0000-0002-2301-1066)
- Ana Bontić (ORCID: https://orcid.org/0000-0002-8209-8552)
- Aleksandra Kezić (ORCID: https://orcid.org/0000-0003-1790-7955)
- Milan Kostić (ORCID: https://orcid.org/0000-0003-4680-5835)
- Kristina Petrović
- Milorad Stojadinović (ORCID: https://orcid.org/0000-0002-1332-6961)
- Selena Gajić (ORCID: https://orcid.org/0000-0002-9359-261X)
- Marko Baralić (ORCID: https://orcid.org/0000-0001-5585-9793)
- Jelena Žunić
- Lara Hadži-Tanović
- Kristina Filić (ORCID: https://orcid.org/0009-0002-2763-5244)
- Ivana Mrđa (ORCID: https://orcid.org/0009-0000-6174-0932)
Institutions
- University of Belgrade (RS)
Publication Details
- Journal
- Metabolites
- Published
- 2025-04-13
- DOI
- https://doi.org/10.3390/metabo15040271
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59